195 related articles for article (PubMed ID: 11120601)
1. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
Ashar HR; James L; Gray K; Carr D; McGuirk M; Maxwell E; Black S; Armstrong L; Doll RJ; Taveras AG; Bishop WR; Kirschmeier P
Exp Cell Res; 2001 Jan; 262(1):17-27. PubMed ID: 11120601
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
Mazzocca A; Giusti S; Hamilton AD; Sebti SM; Pantaleo P; Carloni V
Mol Pharmacol; 2003 Jan; 63(1):159-66. PubMed ID: 12488548
[TBL] [Abstract][Full Text] [Related]
3. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.
Sepp-Lorenzino L; Rosen N
J Biol Chem; 1998 Aug; 273(32):20243-51. PubMed ID: 9685373
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
5. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Smalley KS; Eisen TG
Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
7. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
Brassard DL; English JM; Malkowski M; Kirschmeier P; Nagabhushan TL; Bishop WR
Exp Cell Res; 2002 Feb; 273(2):138-46. PubMed ID: 11822869
[TBL] [Abstract][Full Text] [Related]
9. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Peters DG; Hoover RR; Gerlach MJ; Koh EY; Zhang H; Choe K; Kirschmeier P; Bishop WR; Daley GQ
Blood; 2001 Mar; 97(5):1404-12. PubMed ID: 11222387
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
[TBL] [Abstract][Full Text] [Related]
11. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
Feldkamp MM; Lau N; Roncari L; Guha A
Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
13. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
[TBL] [Abstract][Full Text] [Related]
14. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
15. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
[TBL] [Abstract][Full Text] [Related]
16. In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
Loprevite M; Favoni RE; De Cupis A; Scolaro T; Semino C; Mazzanti P; Ardizzoni A
Oncol Rep; 2004 Feb; 11(2):407-14. PubMed ID: 14719076
[TBL] [Abstract][Full Text] [Related]
17. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
Du W; Prendergast GC
Cancer Res; 1999 Nov; 59(21):5492-6. PubMed ID: 10554025
[TBL] [Abstract][Full Text] [Related]
18. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner.
Vogt A; Sun J; Qian Y; Hamilton AD; Sebti SM
J Biol Chem; 1997 Oct; 272(43):27224-9. PubMed ID: 9341167
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.
Desrosiers RR; Cusson MH; Turcotte S; Béliveau R
Int J Cancer; 2005 May; 114(5):702-12. PubMed ID: 15609318
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
